Shoulder Innovations, Inc. · SI
—
—
$7M
$8M
$7M
$9M
$10M
$11M
$12M
$14M
$17M
20-quarter listed-company comparison
Medical - Specialties Stocks
Medical - Specialties: Shoulder Innovations, Inc. owns the largest revenue base AND the fastest current growth.
01 · sector relative strength, before individual stocks
Is Medical - Specialties outperforming S&P 500?
Medical - Specialties has outperformed S&P 500 by 47.1% over the last 52 weeks. Over 13 weeks the gap is a lead of 48%. 1 of 1 covered company currently beats the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Shoulder Innovations, Inc. is the strongest against the sector itself at 0%.
+48.0%Sector vs S&P 500 · 13 weeks
+47.1%Sector vs S&P 500 · 52 weeks
1/1Stocks leading S&P 500
0/1Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Medical - Specialties has outperformed S&P 500 by 47.1% over 52 weeks and 48% over 13 weeks. 1 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. Shoulder Innovations, Inc. leads with revenue of $54 million, based on 1 of 1 comparable companies through Mar 2026.
Companies
1
complete canonical membership
Combined market value
$460M
Shoulder Innovations, Inc.
Revenue growing
1/1
positive TTM year-on-year growth
Beating S&P 500
1/1
positive Mansfield relative strength
Comparing 1 of 1
02 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Shoulder Innovations, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 57.7% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Shoulder Innovations, Inc.SI | 45.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.3/35 Revenue 58.8% · PAT — · OPM change -11.3 pp 71% evidence | 3.0/25 ROCE -9% · OPM -53.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector 0% · RS bench 31.7% · 1Y 73.9%11 of 12 weeks ahead 70% evidence |
| Exact sum: 20.3 + 3 + 10 + 12.5 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
03 · what price has already done
Market action
Shoulder Innovations, Inc. has the strongest one-year price move in Medical - Specialties at +73.9%. It also leads on Mansfield relative strength against the S&P 500 at +31.7%. 1 of 1 covered company is above zero on that measure. Every line covers 314 weekly closes through 2026-08-20.
Price and relative strength
Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Medical - Specialties itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
04 · compare level, then change
Revenue Scale & Growth Durability
Shoulder Innovations, Inc. is the only Medical - Specialties company on this page, with Revenue of $54 million. The same company also holds the highest Revenue growth, at 58.8%. That is the only usable Revenue reading on this page, current through Mar 2026. Its Revenue series carries 9 reported observations across the 11-quarter window.
What the numbers say: Shoulder Innovations, Inc. is the scale leader at $54 million, Shoulder Innovations, Inc.'s growth is 58.8% from a $54 million base, with 9 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderShoulder Innovations, Inc. · $54 million
GapNot enough peers
Persistence5/5 recent comparable periods
Coverage1/1 companies · 9 observations
Investor read: Shoulder Innovations, Inc. is the scale benchmark; Shoulder Innovations, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Shoulder Innovations, Inc.'s growth falls below Shoulder Innovations, Inc.'s for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
1/1 level · 1/1 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Shoulder Innovations, Inc. SI | $17M | 70% | Mar 2026 |
Full 11-quarter history · every available company
Revenue · reported quarter history
Revenue growth · reported quarter history
Shoulder Innovations, Inc. · SI
—
—
—
—
—
—
43%
38%
71%
56%
70%
05 · compare level, then change
Operating Economics & Margin Trend
Shoulder Innovations, Inc. is the only Medical - Specialties company on this page, with OPM of -53.7%. The same company also holds the highest Margin change, at -11.3 percentage points. That is the only usable OPM reading on this page, current through Mar 2026. Its OPM series carries 9 reported observations across the 11-quarter window.
What the numbers say: Shoulder Innovations, Inc. leads both opm at -53.7% and margin change at -11.3 percentage points.
LeaderShoulder Innovations, Inc. · -53.7%
GapNot enough peers
Persistence1/5 recent comparable periods
Coverage1/1 companies · 9 observations
Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Shoulder Innovations, Inc. SI | -54% | −11.3 pp | Mar 2026 |
Full 11-quarter history · every available company
OPM · reported quarter history
Shoulder Innovations, Inc. · SI
—
—
-45%
-48%
-52%
-41%
-42%
-53%
-65%
-59%
-54%
Margin change · reported quarter history
Shoulder Innovations, Inc. · SI
—
—
—
—
—
—
+2.9 pp
−5.0 pp
−12.9 pp
−18.5 pp
−11.3 pp
06 · compare level, then change
Profit Scale & Acceleration
Shoulder Innovations, Inc. is the only Medical - Specialties company on this page, with Net profit of $44 million net cash. That is the only usable Net profit reading on this page, current through Mar 2026. Its Net profit series carries 9 reported observations across the 11-quarter window.
What the numbers say: Shoulder Innovations, Inc. leads net profit at $44 million net cash; the second comparison lacks enough current evidence.
LeaderShoulder Innovations, Inc. · $44 million net cash
GapNot enough peers
PersistenceNot enough history
Coverage1/1 companies · 9 observations
Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
—Not enough comparable data—
Net profit · company comparison
1/1 level · 0/1 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Shoulder Innovations, Inc. SI | $-8M | — | Mar 2026 |
Full 11-quarter history · every available company
Net profit · reported quarter history
Shoulder Innovations, Inc. · SI
—
—
$-4M
$-4M
$-4M
$-4M
$-5M
$-19M
$-9M
$-8M
$-8M
No consistent historical series is available for profit growth.
07 · compare level, then change
Return On Capital Employed
Shoulder Innovations, Inc. is the only Medical - Specialties company on this page, with ROCE of -9%. The same company also holds the highest ROCE change, at +8 percentage points. That is the only usable ROCE reading on this page, current through Mar 2026. Its ROCE series carries 9 reported observations across the 11-quarter window.
What the numbers say: Shoulder Innovations, Inc. leads ROCE at -9%. Shoulder Innovations, Inc. has the strongest latest improvement at +8 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderShoulder Innovations, Inc. · -9%
GapNot enough peers
Persistence2/5 recent comparable periods
Coverage1/1 companies · 9 observations
Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Shoulder Innovations, Inc. SI | -9.0% | +8.0 pp | Mar 2026 |
Full 11-quarter history · every available company
ROCE · reported quarter history
Shoulder Innovations, Inc. · SI
0.0%
0.0%
—
—
-9.1%
-8.3%
-17%
-18%
-7.7%
-8.9%
-9.0%
ROCE change · reported quarter history
Shoulder Innovations, Inc. · SI
—
—
—
—
−9.1 pp
−8.3 pp
—
—
+1.4 pp
−0.6 pp
+8.0 pp
08 · not available
Valuation Against Growth & Quality
No company in this Medical - Specialties comparison reports valuation on a comparable basis, so there is nothing to rank here — 0 of 1 company has a usable current reading. The section is shown rather than removed so an unavailable metric is not mistaken for one that was quietly left out. Filings were read through Mar 2026.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
09 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Medical - Specialties comparison names 5 specific ways its own evidence can mislead, all listed below. The one company here reports on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- Thin comparisons: Valuation have fewer than three usable current readings.
10 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 1 Medical - Specialties company, normalized to a common $ scale and a shared quarter axis of up to 11 quarters each. Fundamentals run through Mar 2026 and market data through 2026-08-20. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Mar 2026 · up to 11 quarters per company
Market dataThrough 2026-08-20 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
11 · questions investors ask, short speakable answers
Medical - Specialties company comparison FAQs
These 19 answers restate the Medical - Specialties comparison above in question form. Every one is computed from the same 1 company and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-08-20. Nothing here is estimated, and none of it is a recommendation.
Is the Medical - Specialties sector outperforming S&P 500?
Medical - Specialties has outperformed S&P 500 by 47.1% over 52 weeks and 48% over 13 weeks. 1 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself.
Which Medical - Specialties company is largest by revenue?
Shoulder Innovations, Inc. leads with revenue of $54 million, based on 1 of 1 comparable companies through Mar 2026.
Which Medical - Specialties company is growing fastest?
Shoulder Innovations, Inc. has the fastest current revenue growth at 58.8%, across 1 of 1 comparable companies.
Which Medical - Specialties company has the strongest 4-Factor Sector Score?
Shoulder Innovations, Inc. ranks first at 45.8/100 with 57.7% evidence confidence. The score prioritizes research; it is not a buy recommendation.
How much history does this Medical - Specialties comparison include?
The page compares up to 11 reported quarters per company for fundamentals, returns and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Which Medical - Specialties company is the biggest?
Shoulder Innovations, Inc. is the largest, with trailing-twelve-month revenue of $54 million. That covers 1 of 1 companies with comparable reporting through Mar 2026.
Which Medical - Specialties company has the best profit margins?
Shoulder Innovations, Inc. has the highest operating margin at -53.7%, from 1 of 1 comparable companies. Shoulder Innovations, Inc. shows the biggest recent improvement, at -11.3 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Medical - Specialties company makes the most profit?
Shoulder Innovations, Inc. earns the most, at $44 million of trailing-twelve-month net profit, from 1 of 1 comparable companies.
Which Medical - Specialties company earns the highest return on capital?
Shoulder Innovations, Inc. leads on return on capital employed at -9%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Is the Medical - Specialties sector beating the market?
Medical - Specialties has outperformed S&P 500 by 47.1% over the last 52 weeks and 48% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Medical - Specialties stock has the strongest price momentum?
Shoulder Innovations, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Medical - Specialties company scores highest for research priority?
Shoulder Innovations, Inc. scores 45.8 out of 100 with 57.7% evidence confidence, from 20.3 points on growth and earnings, 3 on capital efficiency, 10 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Medical - Specialties companies does this comparison cover, and over what period?
It compares 1 listed companies over up to 11 reported quarters of fundamentals, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Medical - Specialties sector?
The 1 Medical - Specialties companies on this page carry $460 million of combined market value. Shoulder Innovations, Inc. is the largest at $460 million, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.
How is the Medical - Specialties sector performing?
1 of the 1 covered Medical - Specialties companies are beating S&P 500 on Mansfield relative strength. The sector itself is 47.1% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.
How many Medical - Specialties stocks are listed in the US?
This comparison covers 1 listed Medical - Specialties companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Mar 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.
Not SEBI Registered !! Not Investment advice !!